Acute Interstitial Nephritis with Glomerular Capillary IgA Deposition Following SARS-CoV-2 mRNA Vaccination

  • Hishida Erika
    Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
  • Ono Yuko
    Department of Diagnostic Pathology, Dokkyo Medical University, Japan
  • Oe Kazuho
    Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
  • Imai Toshimi
    Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
  • Yoshizawa Hiromichi
    Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
  • Nakaya Takeo
    Department of Pathology, Jichi Medical University, Japan
  • Kawata Hirotoshi
    Department of Pathology, Jichi Medical University, Japan
  • Akimoto Tetsu
    Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
  • Saito Osamu
    Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan
  • Nagata Daisuke
    Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Japan

抄録

<p>We herein report a case of acute kidney injury (AKI) presenting as acute interstitial nephritis (AIN) after the first dose of the BNT162b2 mRNA vaccine against coronavirus disease 2019 (COVID-19). A 69-year-old man with a history of diabetes and hypertension presented with AKI 4 days after receiving the vaccine. Despite the administration of methylprednisolone pulse treatment, his renal function worsened, which prompted us to initiate temporal hemodialysis. His renal function subsequently improved, and a renal biopsy confirmed AIN and glomerular capillary IgA deposition without apparent crescents. The clinical history and histological findings suggest a relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and AIN as a rare side effect. </p>

収録刊行物

  • Internal Medicine

    Internal Medicine 62 (16), 2381-2387, 2023-08-15

    一般社団法人 日本内科学会

参考文献 (45)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ